

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

**In re:**

**PURDUE PHARMA L.P., et al.,  
  
Debtors.<sup>1</sup>**

**Chapter 11**

**Case No. 19-23649 (RDD)**

**(Jointly Administered)**

**ORDER GRANTING THE APPLICATION OF REED SMITH LLP AS AN ORDINARY  
COURSE PROFESSIONAL FOR COMPENSATION FOR SERVICES RENDERED IN  
EXCESS OF THE TIER 1 OCP CAP FOR THE PERIOD FROM MAY 1, 2021  
THROUGH AUGUST 31, 2021**

Upon consideration of the application, dated November 10, 2021 (the “**Application**”) filed by Reed Smith LLP (“**Reed Smith**”) pursuant to sections 327 and 330 of title 11 of the United States Code (the “**Bankruptcy Code**”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “**Bankruptcy Rules**”) and the *Order Authorizing Debtors to Employ Professionals Used in the Ordinary Course of Business Nunc Pro Tunc to the Petition Date* [ECF No. 548] (the “**OCP Order**”), seeking allowance of compensation for actual and necessary professional services in excess of the Tier 1 OCP Cap<sup>2</sup> in the amount of \$485,527.25 from May 1, 2021 through August 31, 2021 (the “**Fee Period**”); and an independent fee examiner (the “**Fee Examiner**”) having been appointed in these cases in accordance with the *Order Authorizing Appointment of Independent*

---

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

<sup>2</sup> Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the OCP Order

*Fee Examiner Pursuant to 11 U.S.C. § 105(a) and Modifying Interim Compensation Procedures for Certain Professionals Employed Pursuant to 11 U.S.C. § 327* [ECF No. 1023] (the “**Fee Examiner Order**”); and the Fee Examiner having reviewed the Application in accordance with the Fee Examiner Order; and the Fee Examiner and Reed Smith having agreed to the recommended fee reductions as set forth on **Schedule A** hereto; and the Fee Examiner having no objection to payment of Reed Smith’s fees in the amount set forth on **Schedule A** hereto under the column heading “Amount of Fees in Excess of Tier 1 OCP Cap Allowed”; and due and sufficient notice having been provided pursuant to Bankruptcy Rules 2002(a)(6) and (c)(2) and the OCP Order, and it appearing that no other or further notice need be provided; and a hearing having been held on December 16, 2021 to consider the Application (the “**Hearing**”); and the Court having jurisdiction over this matter pursuant to 28 U.S.C. §§ 157(a)-(b) and 1334(b) and the Amended Standing Order of Reference M-431, dated January 31, 2012 (Preska, C.J.); and this matter being a core proceeding under 28 U.S.C. § 157(b); and venue being proper before the Court pursuant to 28 U.S.C. §§ 1408 and 1409; and upon the record of all of the proceedings had before the Court; and there being no objections to the relief granted herein; and it appearing that the amount set forth on **Schedule A** for which compensation is allowed hereby was actual, reasonable, and necessary; and good and sufficient cause appearing therefor,

IT IS HEREBY ORDERED THAT:

1. The Application is granted as set forth herein.
2. Reed Smith is awarded compensation for professional services rendered during the Fee Period in excess of the Tier 1 OCP Cap in the amount set forth on **Schedule A** hereto under the column heading “Amount of Fees in Excess of Tier 1 OCP Cap Allowed.”

3. The Debtors are authorized and directed to pay Reed Smith promptly the amounts of fees approved by this Order, to the extent such amounts have not previously been paid.

4. This Court shall retain jurisdiction to hear and determine all matters arising from or related to this Order.

Dated: December 20, 2021  
White Plains, New York

Robert D. Drain  
HONORABLE ROBERT D. DRAIN  
UNITED STATES BANKRUPTCY JUDGE

**Schedule A**

**Application for Fees in Excess of the Tier 1 OCP Cap**

**Case No:** 19-23649 (RDD)

**Case Name:** In re Purdue Pharma L.P., *et al.*

Applicant	Date and Docket Number of Application	Time Period Covered by Application	Amount of Fees in Excess of Tier 1 OCP Cap Requested	Agreed Recommended Reduction of Fees	Amount of Fees in Excess of Tier 1 OCP Cap Allowed
Reed Smith LLP	November 10, 2021 ECF No. 4090	5/01/2021 – 8/31/2021	\$485,527.25	\$12,614.50	\$472,912.75

Date Order Signed: 12/20/2021

Initials: RDD USBJ